Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Merus Partners With Cancer Centers in Netherlands, Japan to ID Patients for eNRGy Trial

The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.

Arbor Biotechnologies Licenses Gene Editing Tech to Lonza

Basel, Switzerland-based Lonza will be able to use Arbor's proprietary CRISPR technology in its bioproduction products and services.

Adaptive Biotechnologies, Q2 Solutions Sign Marketing Agreement for ImmunoSeq Assay

Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.

Servier, Celsius Therapeutics Partner to Identify Colorectal Cancer Drug Targets

Servier will have an exclusive option to research, develop, and commercialize products for up to three of the targets identified by Celsius.

Genosity Inks Deal With Gemini Therapeutics to Develop Assay for AMD Clinical Trial Patient Selection

The assay will be used to select patients for enrollment in a Phase IIa study of Gemini Therapeutics' dry age-related macular degeneration drug GEM103.